Triple-positive breast cancer (TPBC), i.e. HER2-positive (HER2+) and hormone receptors-positive breast cancer, is a specific subgroup of breast cancers. TPBC biology is characterized by strong mutual interactions between signaling pathways stimulated by estrogens and HER2 amplification. The present study aims to carry out a population-based analysis of treatment outcomes in a cohort of hormone receptor (HR) positive and negative breast cancer patients who were treated with anti-HER2 therapy in the Czech Republic. The BREAST research database was used as the data source for this retrospective analysis. The database covers approximately 95% of breast cancer patients treated with targeted therapies in the Czech Republic. The analysis included 6,122 HER2-positive patients. The patients were divided into two groups, based on estrogen receptor (ER) or progesterone receptor (PR) positivity: hormone receptor negative (HR-) patients had both ER- and PR-negative tumors (n=2,518), unlike positive (HR+) patients (n=3,604). HR+ patients were more often diagnosed premenopausal at the time of diagnosis, presented more often at stage I or II and their tumors were less commonly poorly differentiated. The overall survival (OS) was significantly higher in subgroups of HR+ patients according to treatment setting. When evaluated by stages, significantly higher OS was observed in HR+ patients diagnosed at stages II, III, and IV and regardless of tumor grade.

1st Faculty of Medicine Charles University Prague Czech Republic

Department of Comprehensive Cancer Care Masaryk Memorial Cancer Institute Brno Czech Republic

Department of Medical and Radiation Oncology Pardubice Hospital Pardubice Czech Republic

Department of Oncology 1st Faculty of Medicine Charles University and Thomayer Hospital Prague Czech Republic

Department of Oncology and Radiotherapy University Hospital Hradec Kralove Hradec Kralove Czech Republic

Department of Oncology General University Hospital Prague Prague Czech Republic

Department of Oncology Palacky University Medical School and Teaching Hospital Olomouc Czech Republic

Department of Oncology University Hospital in Motol Prague Czech Republic

Faculty of Health Studies University of Pardubice Pardubice Czech Republic

Faculty of Medicine and Dentistry Palacky University Olomouc Czech Republic

Faculty of Medicine in Hradec Kralove Charles University Hradec Kralove Czech Republic

Institute of Biostatistics and Analyses Faculty of Medicine Masaryk University Brno Czech Republic

Radiology Centre Multiscan Ltd Pardubice Czech Republic

The Fingerland Department of Pathology Faculty of Medicine Charles University and University Hospital Hradec Kralove Czech Republic

Citace poskytuje Crossref.org

Impact of Hormone Receptor Status on the Behaviour of HER2+ Breast Cancer